VICTORIA, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced that it will host a virtual key opinion leader (KOL) event on Friday, May 9, 2025 at 9:00 AM ET. To register, click here. The event will feature Evan Dellon, MD, MPH (University ...

Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third quarter of 2026 Company to host webinar to discuss updated data from the RESOLVE trial on May 9th VICTORIA, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Di ...

Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GIAt 9 months active drug continued to be released into the esophagus in patients at a rate similar to what was seen at the 3- and 6-month time points. This is an unprecedented result with an injectable delivery system in patients with EoEAlso, at 9 months patients demonstrated sustained or improved treatment outcomes compared t ...

Core Viewpoint - Eupraxia Pharmaceuticals Inc. is actively participating in multiple upcoming investor and scientific conferences to present its clinical data and advancements in drug delivery technology, particularly focusing on its proprietary DiffuSphere™ technology and ongoing clinical trials for its product candidates [1][9]. Conference Presentations - The company will present at the Osteoarthritis Research Society International World Congress from April 24-27, 2025, with a poster on EP-104IAR, highlighting sustained pain response in knee osteoarthritis patients [2][3]. - At the Digestive Disease Week Annual Meeting from May 3-6, 2025, data from the Phase 1b study of EP-104GI for eosinophilic esophagitis will be presented, including results from the ongoing RESOLVE trial [4][5]. - The CEO will present at the Bloom Burton & Co. Healthcare Investor Conference on May 5, 2025, and participate in investor meetings [5][6]. Product Development - Eupraxia's EP-104GI is in a Phase 1b/2a trial for eosinophilic esophagitis, utilizing a unique local delivery method via injection into the esophageal wall [10]. - The company recently completed a Phase 2b clinical trial (SPRINGBOARD) for EP-104IAR, which met its primary endpoint and three of four secondary endpoints, indicating potential for effective treatment in knee osteoarthritis [10]. Technology Overview - The DiffuSphere™ technology is designed for targeted drug delivery, aiming to improve the safety, tolerability, efficacy, and duration of effect of existing and novel drugs, with applications extending beyond pain and inflammatory gastrointestinal diseases to oncology and infectious diseases [9][10].

Core Insights - Eupraxia Pharmaceuticals Inc. reported financial results for Q4 2024, highlighting a net loss reduction and successful clinical trial data for its product EP-104GI [1][4][2] Financial Performance - The company incurred a net loss of $7.5 million in Q4 2024, an improvement from a net loss of $10.6 million in Q4 2023, attributed to lower research and development costs and reduced expenses [4] - Cash reserves increased to $33.1 million as of December 31, 2024, up from $19.3 million at the end of Q4 2023, providing sufficient funding for clinical trials and operational needs into Q3 2026 [5] Clinical Developments - Positive data from the Phase 1b/2a RESOLVE trial for EP-104GI indicated improved tissue health and symptom reduction in eosinophilic esophagitis patients, with higher doses showing better outcomes [2][13] - The company also completed a Phase 2b trial (SPRINGBOARD) for EP-104IAR, which met its primary endpoint and three of four secondary endpoints [13] Operational Highlights - The appointment of Dr. Amanda Malone as Chief Operating and Scientific Officer was announced, along with the return of Alex Rothwell as Chief Financial Officer [6] - The company presented significant trial data at various medical conferences, receiving accolades for its research quality [6] Market and Trade Considerations - Management is monitoring the potential impact of proposed tariffs on Canadian goods by the U.S. government and retaliatory tariffs from Canada, assessing their implications for the company's operations [8][10] - Eupraxia sources its active pharmaceutical ingredients from the U.S. and maintains U.S. dollar balances to mitigate exchange rate fluctuations [9]

Core Insights - Eupraxia Pharmaceuticals announced positive clinical data from its ongoing RESOLVE Phase 1b/2a trial for EP-104GI, aimed at treating eosinophilic esophagitis (EoE) [1][3] - The trial has shown improvements in both tissue health and symptom relief, with no serious adverse events reported [3][5] Company Overview - Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focused on precision local drug delivery, particularly for conditions with high unmet medical needs [14][15] - The company utilizes its proprietary DiffuSphere™ technology to facilitate targeted drug delivery, aiming to improve safety and efficacy compared to traditional methods [14] Clinical Trial Details - The RESOLVE trial is a multi-center, open-label, dose-escalation study evaluating the safety and efficacy of EP-104GI in adults with active EoE [9] - Cohort 6 of the trial received 16 injections of 4 mg EP-104GI, targeting the lower three-quarters of the esophagus, resulting in significant improvements in symptom relief and tissue health [4][5] Key Findings from the RESOLVE Trial - Cohort 6 demonstrated the highest symptom relief scores (SDI) and the greatest improvement in tissue health scores (EoEHSS) to date [5][6] - A mean reduction of 94% in peak eosinophil counts (PEC) was observed, with a 62% remission rate across biopsy sites [6][8] - No serious adverse events or cases of oral or gastrointestinal candidiasis were reported in any of the cohorts [5][6] Future Expectations - Cohort 7 is fully enrolled, with 12-week data expected in late Q2 2025 [10] - The company plans to explore higher dosing levels and expanded esophageal coverage in future cohorts based on the positive outcomes observed [3][5]

Core Insights - Eupraxia Pharmaceuticals Inc. has introduced new pharmacokinetic data from its Phase 2a Eosinophilic Esophagitis program, highlighting the capabilities of its DiffuSphere™ platform for precise drug delivery [1][4][9] Group 1: DiffuSphere™ Technology - DiffuSphere™ enables targeted drug delivery with a flat, stable, and long-lasting release profile, minimizing adverse effects associated with conventional drug delivery methods [2][17] - The technology consists of a pure drug crystal encased in a polymer shell, allowing for controlled release and high concentrations in target tissues while reducing systemic exposure [3][17] - Clinical trials have demonstrated that a single injection of DiffuSphere™ can maintain therapeutic drug levels for over six months, significantly improving treatment outcomes for conditions like eosinophilic esophagitis and osteoarthritis [5][6] Group 2: Clinical Trial Results - In the RESOLVE trial, DiffuSphere™ showed a treatment duration exceeding six months with a steady drug level of 1.5 pg/ml maintained in patients receiving 4 mg of fluticasone propionate [5] - The Phase 2b study of EP-104IAR for osteoarthritis demonstrated significant pain relief for up to 22 weeks, with no adverse effects on blood glucose metabolism or adrenal function [6][12] - Eupraxia's clinical data supports the efficacy of DiffuSphere™ in improving key disease measures, including patient symptoms and tissue health [5][9] Group 3: Broader Applications - DiffuSphere™ has shown versatility across various drug classes and anatomical locations, including intraarticular, intraesophageal, and intravitreal applications [8][17] - The technology has been successfully tested with local anesthetics and anti-infective agents, indicating its potential for diverse therapeutic uses [8][17] - Eupraxia aims to leverage DiffuSphere™ for future treatments in oncology and infectious diseases, expanding its application beyond pain and inflammatory gastrointestinal diseases [17][18]

Core Insights - Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on optimizing drug delivery through its proprietary DiffuSphere™ technology, which addresses significant unmet medical needs [1][5] - The company will present a poster at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting, highlighting its research on EP-104IAR, a long-acting intra-articular injection for osteoarthritis [1][4] Company Overview - Eupraxia specializes in developing locally delivered, extended-release products aimed at therapeutic areas with high unmet medical needs [5] - The DiffuSphere™ technology is designed to facilitate targeted drug delivery, potentially improving safety, tolerability, efficacy, and duration of effect compared to traditional methods [5] Event Details - The ACR Convergence 2024 Annual Meeting will take place in Washington, D.C. from November 14-19, 2024, providing a platform for education and research in rheumatology [3] - Eupraxia's poster presentation will focus on the sustained improvement in pain for subjects with moderate baseline pain and BMI less than 30, based on a Phase 2 study [4]

EoE affects more than 450,000 people in the United States and has been identified by the American Gastroenterological Association as rapidly increasing in both incidence and prevalence Registration for the webinar now open to the public by visiting EPRXNOV1524.TribePublic.com VICTORIA, BC, Nov. 13, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to o ...

One of three patients in Cohort 5 achieved complete histological remission at 12 weeks. Consistent improvement in patient-reported outcomes with six of six evaluable patients in the fourth and fifth cohorts experiencing a reduction in symptom (SDI1) scores at 12 weeks. At 24 weeks, the fourth cohort experienced the largest average reduction in SDI scores of all cohorts to date. The fifth cohort continued to show improved patient outcomes with the greatest percentage change in histology (EoEHSS2) scores of ...